DiscoverLab Rats to Unicorns
Lab Rats to Unicorns
Claim Ownership

Lab Rats to Unicorns

Author: John Flavin

Subscribed: 7Played: 89
Share

Description

Lab Rats to Unicorns is a podcast that aims to demystify the process of creating a great company in life sciences. Under the guidance of our host, John Flavin, you will hear personal stories of creation, be able to understand how great companies are created, and get insights into the many ways that you as an individual can engage in the creation of tomorrow’s life science companies. From the lab rat, signifying the process of invention and discovery, to the unicorn, signifying market success, there are a thousand players and ways in which people can contribute to the creation of great companies.
98 Episodes
Reverse
Episode DescriptionIn this episode of Lab Rats to Unicorns, John Flavin sits down with Ryan Beal, M.D., founder and CEO of Dyve Biosciences. Ryan traces his path from medicine and consulting to biotech entrepreneurship, and how Dyve evolved from an early skincare concept into a transdermal drug delivery platform with applications in gout and oncology.Ryan explains the science behind tumor acidity, why the acidic environment surrounding tumors can suppress immune activity and reduce the effectiveness of cancer therapies, and how Dyve’s lead oncology program, DYV800, is designed to overcome a longstanding drug delivery challenge. He also discusses the company’s work with Moffitt Cancer Center as it prepares to move the approach into cancer patients.The conversation takes a deeply personal turn as Ryan shares his own cancer diagnosis and experience undergoing chemotherapy, surgery, and radiation while leading Dyve. He and John discuss how becoming a patient changed his perspective on urgency, the importance of a strong team, learning from skepticism, and why curiosity, perseverance, and gratitude continue to guide his work.
In this episode of Lab Rats to Unicorns, John Flavin sits down with Alexis Borisy, a biotechnology entrepreneur and investor who has helped build companies including Foundation Medicine, Blueprint Medicines, and Revolution Medicines. Today, Alexis is the co-founder and operating chairman of Curie.Bio, where he is working to rethink how early-stage biotech companies are built.Alexis traces his journey from aspiring academic to founding CombinatoRx in his twenties, reflecting on the experiences that introduced him to biotechnology entrepreneurship. He discusses navigating the industry's boom-and-bust cycles, overcoming skepticism, and why the possibility of improving patients' lives continues to drive his work.The conversation also explores the unexpected evolution of Revolution Medicines, the importance of building adaptable teams, and Alexis's framework for evaluating promising science. He shares why even successful companies often face moments when their ideas seem unlikely to succeed.Looking ahead, Alexis explains how Curie.Bio is helping founders access the expertise and resources needed to develop medicines more efficiently. He and John discuss the changing economics of biotechnology, why great science can emerge from anywhere, and the importance of building companies that can adapt as they grow.Special thanks to the Chicago Biomedical Consortium (CBC) for helping make this conversation possible! Alexis will also deliver the keynote at CBC's Midwest BioBuilders Summit on November 12 in Chicago. Learn more: https://www.thegreenhousecbc.org/ecosystem/biocapital-summit/
In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Vilasack Thammavongsa and Dr. Dominique Missiakas, co-founders of Immunartes, a biotechnology company developing new approaches to prevent serious Staphylococcus aureus infections.Dominique and Vilasack trace the scientific curiosity that drew them to infectious disease and explain why S. aureus, a pathogen that can live harmlessly on humans while also causing serious disease, became the focus of their work. They discuss how Immunartes is taking a different approach by targeting the mechanisms the bacteria use to manipulate and evade the immune system.The conversation also explores the long path from academic discovery to biotechnology company, including the shift from basic research to product development, the importance of de-risking, and the validation they received from organizations including the NIH and CARB-X.Today, Immunartes is developing both a vaccine for durable protection and a monoclonal antibody for immediate protection in higher-risk patients. Vilasack and Dominique reflect on moving the science toward the clinic, building a multidisciplinary team, and the potential for their approach to reshape how serious bacterial infections are prevented.
In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Jeremy Levin, a physician, scientist, biotech executive, and longtime leader in the pharmaceutical industry. Jeremy has held senior roles across Genzyme, Novartis, Bristol-Myers Squibb, and Teva, and today serves as Executive Chairman of Ovid Therapeutics. Throughout his career, he has helped shape major advances in biotechnology, from the industry’s early days to the rise of immuno-oncology and new approaches to neurological disease. Jeremy traces his journey from growing up on a farm in South Africa and moving between countries as a refugee to studying at Oxford and Cambridge and eventually entering the emerging U.S. biotech industry. He explains how his training as a physician and scientist has remained central to his career and why he sees companies, capital, and strategy ultimately as tools for getting better medicines to more patients. The conversation explores defining moments in Jeremy’s career, including learning the business of biotech at Genzyme and developing the “String of Pearls” strategy at Bristol-Myers Squibb. That approach helped Bristol build new capabilities in biologics and make a bold bet on immuno-oncology at a time when much of the industry remained skeptical. Jeremy also discusses returning to entrepreneurship with Ovid Therapeutics to pursue neurological diseases that much of pharma had abandoned. He reflects on clinical failure, the importance of patient organizations, and why progress often requires being willing to “put your neck on the line.” The episode closes with his perspective on the future of American biotechnology and the need to support science, innovation, and public trust to keep the next generation of breakthroughs moving forward.
In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Kiran Musunuru, a cardiologist, geneticist, professor at the University of Pennsylvania, and leading expert in gene editing. Kiran’s research spans cardiovascular, metabolic, and rare genetic diseases, with a focus on turning advances in human genetics and CRISPR into therapies that address the underlying causes of disease. He is also a co-founder of Verve Therapeutics and helped lead the development of a personalized gene-editing treatment for infant KJ Muldoon. Kiran traces the path that brought him to gene editing, from growing up with a cardiologist father and pursuing combined medical and scientific training to recognizing the potential of human genetics, stem cells, and eventually CRISPR. He explains how his willingness to adopt new technologies led his lab from early tools like zinc finger nucleases and TALENs to CRISPR, base editing, and prime editing. That progression ultimately opened the possibility of not simply treating symptoms, but making precise changes to DNA that could turn off disease-causing genes or repair genetic mutations at their source. Throughout the conversation, Kiran shares how experiments targeting the cholesterol gene PCSK9 led to the idea of a one-time treatment for cardiovascular disease and ultimately to the creation of Verve Therapeutics. He discusses his unexpected journey into entrepreneurship, Verve’s progression into human trials and acquisition by Eli Lilly, and his return to academia to apply the same gene-editing platform to rare diseases. The episode culminates with the remarkable story of KJ, whose personalized base-editing therapy was designed and produced in roughly six months, as well as Kiran’s larger vision for transforming one-off treatments into a scalable platform capable of reaching patients around the world.
loading
Comments